Dietary XXXX : a review of metabolism, benefits and side effects.

@entity1 @entity137 @entity731 @entity5 @entity25589 @entity409 @entity37161 @entity74 @entity9541 @entity5068 @entity694 @entity165
Most animal and @entity1 studies show that @entity9541 reduce serum/or plasma total @entity165 and low density lipoprotein (LDL) @entity165 levels. @entity9541 are structurally very similar to @entity165 except that they always contain some substitutions at the C24 position on the @entity5068 side chain. Plasma @entity37161 levels in @entity1 tissue are normally very low due primarily to poor absorption from the intestine and @entity409 compared to @entity165 . @entity9541 are able to be metabolized in the liver into C21 bile acids via liver other than normal C24 bile acids in mammals. It is generally assumed that @entity165 reduction results directly from inhibition of @entity165 absorption through displacement of @entity165 from micelles. Structure-specific effects of individual @entity37161 constituents have recently been shown where saturated @entity9541 are more efficient compared to unsaturated compounds in reducing @entity165 levels. In addition, @entity9541 produce a wide spectrum of therapeutic effects in animals including anti- @entity5 properties. @entity9541 have been shown experimentally to inhibit @entity694 development. With regard to @entity137 , no obvious side effects of @entity37161 have been observed in studies to date, except in individual with @entity25589 , an @entity74 . Further characterization of the influence of various @entity37161 subcomponents on lipoprotein profiles in @entity1 is required to maximize the usefulness of this non-pharmacological approach to reduction of @entity731 in the population.
